{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T18:06:24Z","timestamp":1747159584544,"version":"3.40.5"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ejmech.2023.115455","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T21:17:58Z","timestamp":1683667078000},"page":"115455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Advancing beyond reverse transcriptase inhibitors: The new era of hepatitis B polymerase inhibitors"],"prefix":"10.1016","volume":"257","author":[{"given":"Abhishek","family":"Ranga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarti","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laxmi","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8052-401X","authenticated-orcid":false,"given":"Sachin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priti","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Hepatitis","key":"10.1016\/j.ejmech.2023.115455_bib1"},{"key":"10.1016\/j.ejmech.2023.115455_bib2","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000084","article-title":"What will it take to cure hepatitis B?","volume":"7","author":"Jeng","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ejmech.2023.115455_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/ph14050417","article-title":"Recent advances in hepatitis B treatment","volume":"14","author":"Prifti","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2023.115455_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2023.115455_bib5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115455_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197664","article-title":"Rosmarinic acid is a novel inhibitor for hepatitis b virus replication targeting viral epsilon RNA-polymerase interaction","volume":"13","author":"Tsukamoto","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115455_bib63","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/gtc.12778","article-title":"Establishment of a system for finding inhibitors of \u03b5 RNA binding with the HBV polymerase","volume":"25","author":"Liu","year":"2020","journal-title":"Gene Cell."},{"key":"10.1016\/j.ejmech.2023.115455_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104709","article-title":"Identification and characterization of a novel hepatitis B virus pregenomic RNA encapsidation inhibitor","volume":"175","author":"Jo","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115455_bib66","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jhep.2020.12.006","article-title":"Identification of a novel long-acting 4\u2019-modified nucleoside reverse transcriptase inhibitor against HBV","volume":"74","author":"Higashi-Kuwata","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115455_bib67","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s12250-018-0065-7","article-title":"In vitro anti-hepatitis B virus activity of 2\u2019,3\u2019-dideoxyguanosine","volume":"33","author":"Zhang","year":"2018","journal-title":"Virol. Sin."},{"key":"10.1016\/j.ejmech.2023.115455_bib68","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00535-019-01643-0","article-title":"Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay","volume":"55","author":"Nakajima","year":"2020","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2023.115455_bib69","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejmech.2017.12.042","article-title":"Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors","volume":"144","author":"Qiu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115455_bib70","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jsps.2018.12.008","article-title":"Plant-derived antiviral drugs as novel hepatitis B virus inhibitors: cell culture and molecular docking study","volume":"27","author":"Parvez","year":"2019","journal-title":"Saudi Pharmaceut. J."},{"key":"10.1016\/j.ejmech.2023.115455_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/v12080840","article-title":"Screening and evaluation of novel compounds against hepatitis B virus polymerase using highly purified reverse transcriptase domain","volume":"12","author":"Ohsaki","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2023.115455_bib73","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bmc.2018.02.003","article-title":"2-Arylthio-5-iodo pyrimidine derivatives as non-nucleoside HBV polymerase inhibitors","volume":"26","author":"Wang","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115455_bib82","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.antiviral.2017.06.014","article-title":"Efficacy and cytotoxicity in cell culture of novel \u03b1-hydroxytropolone inhibitors of hepatitis B virus ribonuclease H","volume":"144","author":"Lomonosova","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115455_bib84","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.antiviral.2017.04.012","article-title":"Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles","volume":"143","author":"Edwards","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115455_bib85","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2019.02.005","article-title":"Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors","volume":"164","author":"Edwards","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115455_bib86","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00245-17","article-title":"3-Hydroxypyrimidine-2,4-Diones as novel hepatitis B virus antivirals targeting the viral ribonuclease H","volume":"61","author":"Huber","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115455_bib88","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02441-16","article-title":"Synergistic interactions between hepatitis B virus RNase H antagonists and other inhibitors","volume":"61","author":"Lomonosova","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115455_bib90","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01460-21","article-title":"Efficient inhibition of hepatitis B virus (HBV) replication and cccDNA formation by HBV ribonuclease H inhibitors during infection","volume":"65","author":"Chauhan","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115455_bib92","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fviro.2022.861494","article-title":"Aurintricarboxylic acid suppresses hepatitis B virus replication by inhibition of RNase H activity","volume":"2","author":"Xu","year":"2022","journal-title":"Frontiers in Virology"},{"key":"10.1016\/j.ejmech.2023.115455_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bpg.2017.04.010","article-title":"Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants","volume":"31","author":"Lin","year":"2017","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.ejmech.2023.115455_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115455_bib8","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115455_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.20517\/2394-5079.2016.05","article-title":"Hepatitis B virus molecular biology and pathogenesis","volume":"2","author":"Lamontagne","year":"2016","journal-title":"Hepatoma Res"},{"key":"10.1016\/j.ejmech.2023.115455_bib10","first-page":"150","article-title":"Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment","author":"Winckelmann","year":"2022","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mco.2021.2275","article-title":"Entecavir resistance in a patient with treatment-na\u00efve hbv: a case report","volume":"14","author":"Marino","year":"2021","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.ejmech.2023.115455_bib12","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12072-017-9829-7","article-title":"Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread","volume":"11","author":"Karayiannis","year":"2017","journal-title":"Hepatol Int"},{"year":"2022","series-title":"HIV Antiretroviral Therapy","author":"Kemnic","key":"10.1016\/j.ejmech.2023.115455_bib13"},{"key":"10.1016\/j.ejmech.2023.115455_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","article-title":"Update and latest advances in antiretroviral therapy","volume":"43","author":"Men\u00e9ndez-Arias","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2023.115455_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B virus: advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2023.115455_bib16","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.chembiol.2018.04.011","article-title":"De novo macrocyclic peptide inhibitors of hepatitis B virus cellular entry","volume":"25","author":"Passioura","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.ejmech.2023.115455_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41426-018-0189-8","article-title":"Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B","volume":"7","author":"Zhao","year":"2018","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.ejmech.2023.115455_bib18","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jhep.2022.12.014","article-title":"Discovery of a first-in-class orally available HBV cccDNA inhibitor","volume":"78","author":"Wang","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115455_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/fvl-2019-0133","article-title":"Strategies to eliminate HBV infection: an update","volume":"15","author":"Tang","year":"2020","journal-title":"Future Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection","volume":"159","author":"Zoulim","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115455_bib21","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1021\/acsinfecdis.8b00337","article-title":"Treatment of chronic hepatitis B virus infection using small molecule modulators of nucleocapsid assembly: recent advances and perspectives","volume":"5","author":"Yang","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115455_bib22","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1038\/s41598-018-23525-w","article-title":"Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes","volume":"8","author":"Lucifora","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.115455_bib23","doi-asserted-by":"crossref","first-page":"10188","DOI":"10.1021\/acs.jmedchem.0c00100","article-title":"Discovery of GS-9688 (selgantolimod) as a potent and selective oral toll-like receptor 8 agonist for the treatment of chronic hepatitis B","volume":"63","author":"Mackman","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115455_bib24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115455_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coviro.2018.01.008","article-title":"Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B","volume":"30","author":"Suslov","year":"2018","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.ejmech.2023.115455_bib26","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/17460441.2018.1473372","article-title":"Recent advances in the discovery and development of TLR ligands as novel therapeutics for chronic HBV and HIV infections","volume":"13","author":"Du","year":"2018","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115455_bib27","doi-asserted-by":"crossref","first-page":"391","DOI":"10.33073\/pjm-2020-044","article-title":"Hepatitis B virus: from diagnosis to treatment","volume":"69","author":"Guvenir","year":"2020","journal-title":"Pol. J. Microbiol."},{"key":"10.1016\/j.ejmech.2023.115455_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/ph14050417","article-title":"Recent advances in hepatitis B treatment","volume":"14","author":"Prifti","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2023.115455_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104548","article-title":"Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: an observational case series of South African adults","volume":"129","author":"Mokaya","year":"2020","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.virol.2009.04.023","article-title":"An interdomain RNA binding site on the hepadnaviral polymerase that is essential for reverse transcription","volume":"390","author":"Badtke","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.ejmech.2023.115455_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02161-18","article-title":"RNA-binding motif protein 24 (RBM24) is involved in pregenomic RNA packaging by mediating interaction between hepatitis B virus polymerase and the epsilon element","volume":"93","author":"Yao","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib32","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3390\/v12050570","article-title":"Molecular, evolutionary, and structural analysis of the terminal protein domain of hepatitis B virus polymerase, a potential drug target","volume":"12","author":"Buhlig","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2023.115455_bib33","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1128\/JVI.02575-13","article-title":"Large-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase","volume":"88","author":"V\u00f6r\u00f6s","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01785-16","article-title":"Mapping of functional subdomains in the terminal protein domain of hepatitis B virus polymerase","volume":"91","author":"Clark","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.79.16.10164-10170.2005","article-title":"Identification of an essential molecular contact point on the duck hepatitis B virus reverse transcriptase","volume":"79","author":"Cao","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01196-07","article-title":"Chaperones activate hepadnavirus reverse transcriptase by transiently exposing a C-proximal region in the terminal protein domain that contributes to \u03f5 RNA binding","volume":"81","author":"Stahl","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2217\/fvl.14.113","article-title":"Unveiling the roles of HBV polymerase for new antiviral strategies","volume":"10","author":"Clark","year":"2015","journal-title":"Future Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib38","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1099\/vir.0.031914-0","article-title":"A conserved arginine residue in the terminal protein domain of hepatitis B virus polymerase is critical for RNA pre-genome encapsidation","volume":"92","author":"Shin","year":"2011","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib39","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1016\/j.febslet.2011.11.003","article-title":"Hydrophobic residues of terminal protein domain of hepatitis B virus polymerase contribute to distinct steps in viral genome replication","volume":"585","author":"Shin","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2023.115455_bib40","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1093\/nar\/30.7.1679","article-title":"dNTP versus NTP discrimination by phenylalanine 451 in duck hepatitis B virus P protein indicates a common structure of the dNTP-binding pocket with other reverse transcriptases","volume":"30","author":"Beck","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2023.115455_bib41","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1038\/emi.2013.56","article-title":"Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention","volume":"2","author":"Jones","year":"2013","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.ejmech.2023.115455_bib42","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1128\/JVI.07137-11","article-title":"In vitro epsilon RNA-dependent protein priming activity of human hepatitis B virus polymerase","volume":"86","author":"Jones","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib43","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1128\/JVI.00011-12","article-title":"Extensive mutagenesis of the conserved box E motif in duck hepatitis B virus P protein reveals multiple functions in replication and a common structure with the primer grip in HIV-1 reverse transcriptase","volume":"86","author":"Wang","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00051-22","article-title":"Spacer domain in hepatitis B virus polymerase: plugging a hole or performing a role?","volume":"96","author":"Pley","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib45","first-page":"146","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"year":"2007","series-title":"Role of Glycosaminoglycans for Binding and Infection of Hepatitis B Virus","author":"Leistner","key":"10.1016\/j.ejmech.2023.115455_bib46"},{"key":"10.1016\/j.ejmech.2023.115455_bib47","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2006.05.019","article-title":"Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus","volume":"45","author":"Sun","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115455_bib48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0166-0934(03)00190-3","article-title":"A quantitative method to detect HBV cccDNA by chimeric primer and real-time polymerase chain reaction","volume":"112","author":"Jun-Bin","year":"2003","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.ejmech.2023.115455_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/v13081463","article-title":"Mechanism of hepatitis B virus cccDNA formation","volume":"13","author":"Wei","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2023.115455_bib50","doi-asserted-by":"crossref","first-page":"13122","DOI":"10.1128\/JVI.78.23.13122-13131.2004","article-title":"Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function","volume":"78","author":"Hu","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib51","doi-asserted-by":"crossref","first-page":"11447","DOI":"10.1128\/JVI.74.24.11447-11455.2000","article-title":"In vitro reconstitution of a functional duck hepatitis B virus reverse transcriptase: posttranslational activation by Hsp90","volume":"74","author":"Hu","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib52","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1128\/JVI.02786-12","article-title":"Protein-primed terminal transferase activity of hepatitis B virus polymerase","volume":"87","author":"Jones","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib53","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1099\/0022-1317-81-8-2059","article-title":"Evidence that the first strand-transfer reaction of duck hepatitis B virus reverse transcription requires the polymerase and that strand transfer is not needed for the switch of the polymerase to the elongation mode of DNA synthesis","volume":"81","author":"Gong","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3748\/wjg.v13.i1.65","article-title":"Hepatitis B virus morphogenesis","volume":"13","author":"Bruss","year":"2007","journal-title":"World J. Gastroenterol. : WJG."},{"key":"10.1016\/j.ejmech.2023.115455_bib55","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2033898100","article-title":"Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver","volume":"100","author":"Zhang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2023.115455_bib56","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1128\/jvi.64.2.613-620.1990","article-title":"Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity","volume":"64","author":"Radziwill","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib57","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1128\/jvi.64.11.5553-5558.1990","article-title":"Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase","volume":"64","author":"Chang","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib58","article-title":"The aa 15-17 amino acid sequence in the terminal protein domain of HBV polymerase as a viral factor affecting in vivo as well as in vitro replication activity of the virus: 1072","volume":"58","author":"Uchida","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2023.115455_bib59","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/nsr\/nwv044","article-title":"New insights into hepatitis B virus biology and implications for novel antiviral strategies","volume":"2","author":"Chen","year":"2015","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.ejmech.2023.115455_bib60","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/JVI.02147-07","article-title":"Inhibition of hepadnavirus reverse transcriptase-\u03f5 RNA interaction by porphyrin compounds","volume":"82","author":"Lin","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib61","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00816-12","article-title":"Carbonyl J acid derivatives block protein priming of hepadnaviral P protein and DNA-dependent DNA synthesis activity of hepadnaviral nucleocapsids","volume":"86","author":"Wang","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/11318110-000000000-00000","article-title":"Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action","volume":"49","author":"Bazzoli","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2023.115455_bib72","doi-asserted-by":"crossref","first-page":"7104","DOI":"10.3390\/molecules19067104","article-title":"Synthesis and biological evaluation of novel 2-Arylalkylthio-5-iodine-6-substituted-benzyl-pyrimidine-4(3H)-ones as potent HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"19","author":"Zhang","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.115455_bib74","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.str.2009.09.016","article-title":"Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site","volume":"17","author":"Himmel","year":"2009","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2023.115455_bib75","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1021\/acsinfecdis.8b00045","article-title":"Chemical approaches to inhibiting the hepatitis B virus ribonuclease H","volume":"5","author":"Tavis","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115455_bib76","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1039\/c3cc41191e","article-title":"Antagonism of a zinc metalloprotease using a unique metal-chelating scaffold: tropolones as inhibitors of P. aeruginosa elastase","volume":"49","author":"Fullagar","year":"2013","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2023.115455_bib77","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1016\/j.bmcl.2014.09.037","article-title":"Inhibition of the ANT(2\u2033)-Ia resistance enzyme and rescue of aminoglycoside antibiotic activity by synthetic \u03b1-hydroxytropolones","volume":"24","author":"Hirsch","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115455_bib78","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00018-005-5054-y","article-title":"Tyrosinase inhibitors from natural and synthetic sources: structure, inhibition mechanism and perspective for the future","volume":"62","author":"Kim","year":"2005","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2023.115455_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003125","article-title":"The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes","volume":"9","author":"Tavis","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2023.115455_bib80","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.antiviral.2013.06.007","article-title":"\u03b2-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity","volume":"99","author":"Hu","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115455_bib81","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1128\/AAC.04617-14","article-title":"Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity","volume":"59","author":"Lu","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115455_bib83","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2015.04.002","article-title":"The hepatitis B virus ribonuclease H as a drug target","volume":"118","author":"Tavis","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115455_bib87","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.antiviral.2014.05.007","article-title":"Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity","volume":"108","author":"Cai","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115455_bib89","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01617-21","article-title":"Effects of troponoids on mitochondrial function and cytotoxicity","volume":"66","author":"Bradley","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115455_bib91","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.antiviral.2017.11.008","article-title":"Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice","volume":"149","author":"Long","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115455_bib93","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature08444","article-title":"A human 5\u2019-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage","volume":"461","author":"Ledesma","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115455_bib94","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1128\/JVI.02786-12","article-title":"Protein-primed terminal transferase activity of hepatitis B virus polymerase","volume":"87","author":"Jones","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128401","article-title":"Does tyrosyl DNA phosphodiesterase-2 play a role in hepatitis B virus genome repair?","volume":"10","author":"Cui","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115455_bib96","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00922-20","article-title":"Characterization of the termini of cytoplasmic hepatitis B virus deproteinated relaxed circular DNA","volume":"95","author":"Cai","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib97","doi-asserted-by":"crossref","first-page":"E4244","DOI":"10.1073\/pnas.1409986111","article-title":"Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses","volume":"111","author":"K\u00f6Niger","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2023.115455_bib98","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s41467-021-21850-9","article-title":"Hepatitis B virus cccDNA is formed through distinct repair processes of each strand","volume":"12","author":"Wei","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115455_bib99","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2019.12.009","article-title":"Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication","volume":"72","author":"Wang","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115455_bib100","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1073\/pnas.93.3.1060","article-title":"Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase","volume":"93","author":"Hu","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2023.115455_bib101","doi-asserted-by":"crossref","first-page":"36128","DOI":"10.1074\/jbc.M301069200","article-title":"Efficient Hsp90-independent in vitro activation by Hsc70 and Hsp40 of duck hepatitis B virus reverse transcriptase, an assumed Hsp90 client protein","volume":"278","author":"Beck","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115455_bib102","doi-asserted-by":"crossref","first-page":"9366","DOI":"10.3390\/ijms22179366","article-title":"Role of heat shock proteins (HSP70 and HSP90) in viral infection","volume":"22","author":"Lubkowska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115455_bib103","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1128\/JVI.75.15.6962-6968.2001","article-title":"Human hepatitis B virus polymerase interacts with the molecular chaperonin Hsp60","volume":"75","author":"Park","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib104","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1006\/viro.2002.1496","article-title":"Binding site analysis of human HBV pol for molecular chaperonin, Hsp60","volume":"298","author":"Park","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.ejmech.2023.115455_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.814120","article-title":"Proteomic analyses identify therapeutic targets in hepatocellular carcinoma","volume":"12","author":"Elmas","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2023.115455_bib106","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1016\/j.bbrc.2018.08.065","article-title":"Heat shock protein 70 and heat shock protein 90 synergistically increase hepatitis B viral capsid assembly","volume":"503","author":"Seo","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2023.115455_bib107","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02161-18","article-title":"RNA-binding motif protein 24 (RBM24) is involved in pregenomic RNA packaging by mediating interaction between hepatitis B virus polymerase and the epsilon element","volume":"93","author":"Yao","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib108","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2004.09.029","article-title":"Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function","volume":"119","author":"Yedavalli","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115455_bib109","doi-asserted-by":"crossref","first-page":"13689","DOI":"10.1128\/JVI.02035-14","article-title":"DDX3 DEAD-box RNA helicase is a host factor that restricts hepatitis B virus replication at the transcriptional level","volume":"88","author":"Ko","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jmb.2010.05.029","article-title":"APOBEC1 and APOBEC3 cytidine deaminases as restriction factors for hepadnaviral genomes in non-humans in vivo","volume":"400","author":"Renard","year":"2010","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.115455_bib111","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1742-4690-6-96","article-title":"Human APOBEC1 cytidine deaminase edits HBV DNA","volume":"6","author":"Gonzalez","year":"2009","journal-title":"Retrovirology"},{"key":"10.1016\/j.ejmech.2023.115455_bib112","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1872-034X.2009.00566.x","article-title":"Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection","volume":"39","author":"Abe","year":"2009","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.ejmech.2023.115455_bib113","first-page":"2074","volume":"vol. 12","author":"Zhang","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115455_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2021.114127","article-title":"A mid-throughput HBV replication inhibition assay capable of detecting ribonuclease H inhibitors","volume":"292","author":"Li","year":"2021","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.ejmech.2023.115455_bib115","first-page":"301","article-title":"Hepatitis B virus: DNA polymerase activity of deletion mutants","volume":"47","author":"Kim","year":"1999","journal-title":"Biochem. Mol. Biol. Int."},{"key":"10.1016\/j.ejmech.2023.115455_bib116","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1008175107309","article-title":"Active human hepatitis B viral polymerase expressed in rabbit reticulocyte lysate system","volume":"19","author":"Younhee","year":"1999","journal-title":"Virus Gene."},{"key":"10.1016\/j.ejmech.2023.115455_bib117","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1128\/JVI.00332-09","article-title":"Four conserved cysteine residues of the hepatitis B virus polymerase are critical for RNA pregenome encapsidation","volume":"83","author":"Kim","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115455_bib118","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1128\/jvi.64.11.5324-5332.1990","article-title":"The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation","volume":"64","author":"Bartenschlager","year":"1990","journal-title":"J. Virol."},{"year":"2007","series-title":"Efficacy and Safety of Clevudine Compared with Adefovir in Patients with HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus - ClinicalTrials.Gov","key":"10.1016\/j.ejmech.2023.115455_bib119"},{"key":"10.1016\/j.ejmech.2023.115455_bib120","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00836-20","article-title":"ATI-2173, a novel liver-targeted non-chain-terminating nucleotide for hepatitis B virus cure regimens","volume":"64","author":"Squires","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"year":"2022","series-title":"A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects - ClinicalTrials.Gov","key":"10.1016\/j.ejmech.2023.115455_bib122"},{"year":"2020","series-title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults -ClinicalTrials.Gov","key":"10.1016\/j.ejmech.2023.115455_bib123"},{"key":"10.1016\/j.ejmech.2023.115455_bib124","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J. Hepatol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342300421X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342300421X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T14:51:29Z","timestamp":1730991089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342300421X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":123,"alternative-id":["S022352342300421X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115455","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing beyond reverse transcriptase inhibitors: The new era of hepatitis B polymerase inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115455"}}